LCM
AARD

Laurion Capital Management’s Aardvark Therapeutics AARD Stock Holding History

Laurion Capital Management’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.96M Hold
1,034,459
– – 0.15% 125
2026
Q1 		$3.9M Buy
1,034,459
+19,548
+2% +$203K 0.17% 155
2025
Q4 		$13.3M Sell
1,014,911
-34,810
-3% -$434K 0.5% 43
2025
Q3 		$14M Buy
1,049,721
+60,653
+6% +$684K 0.24% 79
2025
Q2 		$13.4M Buy
989,068
+180,825
+22% +$1.86M 0.24% 85
2025
Q1 		$6.07M Buy
+808,243
New +$9.08M 0.15% 96

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Laurion Capital Management's AARD Position: Q2 2026 in Review

Laurion Capital Management held its Aardvark Therapeutics (AARD) position steady in Q2 2026 at 1,034,459 shares worth $5.96M. The position accounts for 0.15% of the portfolio, ranked #125.

Laurion Capital Management first reported a position in AARD in Q1 2025 and has held it in 6 quarters since. The position peaked at $14M in Q3 2025. 71 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • Laurion Capital Management held 1,034,459 shares of Aardvark Therapeutics worth $5.96M as of Q2 2026.
  • Laurion Capital Management left its Aardvark Therapeutics share count unchanged in Q2 2026.
  • Aardvark Therapeutics made up 0.15% of Laurion Capital Management's portfolio in Q2 2026, its #125 holding.
  • Laurion Capital Management first reported a position in Aardvark Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Laurion Capital Management's Aardvark Therapeutics position peaked at $14M in Q3 2025.
  • 71 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on Laurion Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.